🇺🇸 FDA
Pipeline program

anti-CD19/BCMA-UCAR-T cells

2026-SR-020

Unknown mab active

Quick answer

anti-CD19/BCMA-UCAR-T cells for Rheumatoid Arthritis is a Unknown program (mab) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Rheumatoid Arthritis
Phase
Unknown
Modality
mab
Status
active

Clinical trials